|
1. Jessop ZM, Al-Sabah A, Francis WR, Whitaker IS. Transforming healthcare through regenerative medicine. BMC Med. 2016;14(1):115. doi:10.1186/s12916-016-0669-4 PMid:27510095 PMCid:PMC4980802 2. Iran rises to 7th globally in regenerative medicine following approval of new cell therapy products 2026 [Available from: https://cistc.ir/en/6411/iran-rises-to-7th-globally-in-regenerative-medicine-following-approval-of-new-cell-therapy-products/#:~:text=According%20to%202025%20global%20data,unveiled%20during%20upcoming%20anniversary%20events. 3. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two decades of global progress in authorized advanced therapy medicinal products: an emerging revolution in therapeutic strategies. Front Cell Dev Biol. 2020; 8: 547653. doi:10.3389/fcell.2020.547653 PMid:33392179 PMCid:PMC7773756 4. Marei HE. Stem cell therapy: a revolutionary cure or a pandora's box. Stem Cell Res Ther. 2025; 16(1): 255. doi:10.1186/s13287-025-04334-1 PMid:40405306 PMCid:PMC12096755 5. Honari A, Mahdavi SMH, Nassiran Najafabadi D. Study of the Process and System of Using Stem Cells and Gene Therapy from the Perspective of Iranian Law. Med Law J. 2022;16(57):1017-33. 6. Safardoust A, Ghanei M, Mahboudi F, Pourqasem M, Mirmohammadi S, Moghadasian MM. The current status, trends, and developments in biopharmaceutical policy making in Iran. J Sci Technol Policy Manag. 2025. doi:10.1108/JSTPM-01-2023-0009 7. Karimi F, Mosadeghrad AM, Vaezi M, Janbabaei G, Ghobeishipour H, Nozarian MH, et al. Stem cell transplantation cost in Iran. BMC Health Serv Res. 2025; 25(1):1094. doi:10.1186/s12913-025-13251-1 PMid:40826092 PMCid:PMC12360016 8. Kim DS, Bae S. Impact and challenges of enactment for advanced regenerative medicine in South Korea. Front Bioeng Biotechnol. 2022; 10: 972865. doi:10.3389/fbioe.2022.972865 PMid:36312539 PMCid:PMC9597240 9. Corbett MS, Webster A, Hawkins R, Woolacott N. Innovative regenerative medicines in the EU: a better future in evidence? BMC Med. 2017;15(1):49. doi:10.1186/s12916-017-0818-4 PMid:28270209 PMCid:PMC5341436 10. Azuma K. Regulatory landscape of regenerative medicine in Japan. Curr Stem Cell Rep. 2015; 1(2):118-28. doi:10.1007/s40778-015-0012-6 11. Qiu T, Hanna E, Dabbous M, Borislav B, Toumi M. Regenerative medicine regulatory policies: a systematic review and international comparison. Health Policy. 2020; 124(7):701-13. doi:10.1016/j.healthpol.2020.05.004 PMid:32499078 12. Yokomizo R, Hosoya S, Umezawa A, Okamoto A. Amendment of the Act on the Safety of Regenerative Medicine: A new voyage of regenerative medicine in Japan and the dawn of a new era for young investigators. Regen Ther. 2025; 29:237-46. doi:10.1016/j.reth.2025.03.011 PMid:40230356 PMCid:PMC11995011 13. Makarevich PI, Tkachuk VA. Fundamental and Practical Perspectives in Regenerative Medicine. MDPI; 2024. p. 11508. doi:10.3390/ijms252111508 PMid:39519061 PMCid:PMC11546304 14. Takashima K, Morrison M, Minari J. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan. Stem Cell Reports. 2021;16(6):1425-34. doi:10.1016/j.stemcr.2021.04.017 PMid:34019814 PMCid:PMC8190593 15. Jokura Y, Yano K, Yamato M. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European :union:. J Tissue Eng Regen Med. 2018;12(2):e1056-e62. doi:10.1002/term.2428 PMCid:PMC5836905 16. Matsushita S, Tachibana K, Kusakabe T, Hirayama R, Tsutsumi Y, Kondoh M. The roadmap to approval under Japan's two-track regulatory system: comparing six regenerative medical products. Cell Stem Cell. 2020;27(4):515-8. doi:10.1016/j.stem.2020.09.003 PMid:33007235 17. Beheshtizadeh N, Gharibshahian M, Pazhouhnia Z, Rostami M, Zangi AR, Maleki R, et al. Commercialization and regulation of regenerative medicine products: Promises, advances and challenges. Biomed Pharmacother. 2022; 153:113431. doi:10.1016/j.biopha.2022.113431 PMid:36076549 18. Qiu T, Pochopień M, Hanna E, Liang S, Wang Y, Han R, et al. Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review. Regen Med. 2022;17(3):119-39. doi:10.2217/rme-2021-0083 PMid:35042424
|
_-_Copy.png)
.png){kind=logo}
